Page 32 - Read Online
P. 32

Ossoliński et al. J Cancer Metastasis Treat 2019;5:1  I  http://dx.doi.org/10.20517/2394-4722.2018.63                    Page 11 of 12

               Copyright
               © The Author(s) 2019.


               REFERENCES
               1.   Brawley OW. Prostate cancer epidemiology in the United States. World J Urol 2012;30:195-200.
               2.   Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. Screening and prostate-cancer mortality in a randomized European
                   study. N Engl J Med 2009;360:1320-8.
               3.   Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, et al. Mortality results from the Göteborg randomised population-based prostate-
                   cancer screening trial. Lancet Oncol 2010;11:725-32.
               4.   Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl
                   J Med 2009;360:1310-9.
               5.   Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA
                   2014;311:1143-9.
               6.   Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, et al. Detection of high-grade prostate cancer using a urinary molecular
                   biomarker-based risk score. Eur Urol 2016;70:740-8.
               7.   Govers TM, Hessels D, Vlaeminck-Guillem V, Schmitz-Dräger BJ, Stief CG, et al. Cost-effectiveness of SelectMDx for prostate cancer in
                   four European countries: a comparative modeling study. Prostate Cancer Prostatic Dis 2018; doi:10.1038/s41391-018-0076-3.
               8.   Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012;13:263-9.
               9.   Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell
                   Proteomics 2004;3:367-78.
               10.  Yang J, Zhu Y, Guo H, Wang X, Gao R, et al. Identifying serum biomarkers for ovarian cancer by screening with surface-enhanced laser
                   desorption/ionization mass spectrometry and the artificial neural network. Int J Gynecol Cancer 2013;23:667-72.
               11.  Wright GL Jr, Cazares LH, Leung SM, Nasim S, Adam BL, et al. Proteinchip(R) surface enhanced laser desorption/ionization (SELDI)
                   mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate
                   Cancer Prostatic Dis 1999;2:264-76.
               12.  Ocak S, Chaurand P, Massion PP. Mass spectrometry-based proteomic profiling of lung cancer. Proc Am Thorac Soc 2009;6:159-70.
               13.  Martínez-Aguilar J, Chik J, Nicholson J, Semaan C, McKay MJ, et al. Quantitative mass spectrometry for colorectal cancer proteomics.
                   Proteomics Clin Appl 2013;7:42-54.
               14.  Wu B, Abbott T, Fishman D, McMurray W, Mor G, et al. Ovarian cancer classification based on mass spectrometry analysis of sera. Cancer
                   Inform 2007;2:123-32.
               15.  Nizioł J, Ossoliński K, Ossoliński T, Ossolińska A, Bonifay V, et al. Surface-transfer mass spectrometry imaging of renal tissue on gold
                   nanoparticle enhanced target. Anal Chem 2016;88:7365-71.
               16.  Whelan SA, He J, Lu M, Souda P, Saxton RE, et al. Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in
                   proximal fluid. J Proteome Res 2012;11:5034-45.
               17.  Xue R, Dong L, Zhang S, Deng C, Liu T, et al. Investigation of volatile biomarkers in liver cancer blood using solid-phase microextraction
                   and gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2008;22:1181-6.
               18.  Lucarelli G, Rutigliano M, Galleggiante V, Giglio A, Palazzo S, et al. Metabolomic profiling for the identification of novel diagnostic
                   markers in prostate cancer. Expert Rev Mol Diagn 2015;15:1211-24.
               19.  Ferro M, Lucarelli G, Bruzzese D, Perdonà S, Mazzarella C, et al. Improving the prediction of pathologic outcomes in patients undergoing
                   radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine. Anticancer Res
                   2015;35:1017-23.
               20.  de Vogel S, Ulvik A, Meyer K, Ueland PM, Nygård O, et al. Sarcosine and other metabolites along the choline oxidation pathway in relation
                   to prostate cancer - a large nested case-control study within the JANUS cohort in Norway. Int J Cancer 2014;134:197-206.
               21.  de Cobelli O, Terracciano D, Tagliabue E, Raimondi S, Galasso G, et al. Body mass index was associated with upstaging and upgrading in
                   patients with low-risk prostate cancer who met the inclusion criteria for active surveillance. Urol Oncol 2015;33:201.
               22.  Ferro M, Lucarelli G, Bruzzese D, Di Lorenzo G, Perdonà S, et al. Low serum total testosterone level as a predictor of upstaging and
                   upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. Oncotarget 2017;8:18424-34.
               23.  Sekuła J, Nizioł J, Rode W, Ruman T. Gold nanoparticle-enhanced target (AuNPET) as universal solution for laser desorption/ionization
                   mass spectrometry analysis and imaging of low molecular weight compounds. Anal Chim Acta. 2015;875:61-72.
               24.  Cacciatore S, Zadra G, Bango C, Penney KL, Tyekucheva S, et al. Metabolic profiling in formalin-fixed and paraffin-embedded prostate
                   cancer tissues. Mol Cancer Res 2017;15:439-47.
               25.  Sund M, Kalluri R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev 2009;28:177-83.
               26.  Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007;7:139-47.
               27.  Liu Y, Zuckier LS, Ghesani NV. Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic
                   approach. Anticancer Res 2010;30:369-74.
               28.  Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis 2016;5:e189.
               29.  Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of
                   clinically organ-confined prostate cancer. Urology 2001;57:108-11.
               30.  Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB. Impact of circulating cholesterol levels on growth and intratumoral
                   androgen concentration of prostate tumors. PLoS One 2012;7:e30062.
               31.  Twiddy AL, Leon CG, Wasan KM. Cholesterol as a potential target for castration-resistant prostate cancer. Pharm Res 2011;28:423-37.
               32.  Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, et al. Maintenance of intratumoral androgens in metastatic prostate
   27   28   29   30   31   32   33   34   35   36   37